Compare Ascendis Pharma A/S (ASND) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI Germany (DAX) — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares MSCI Germany (DAX) trades at $40.73. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| ASND | EWG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $44.56 |
52-Week Low | $163.32 | $38.08 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EWG trades at $41.49, down slightly by 0.12% today, with technical indicators showing a bearish bias from moving averages and mixed signals from oscillators. Key financial ratios are unavailable in the provided data, and the stock faces headwinds from European economic policies and interest rate changes. Recent news highlights German healthcare reforms and ECB rate hikes impacting market sentiment.
The outlook for EWG is cautious due to bearish technicals and macroeconomic pressures in Europe. Investment opportunities may arise from potential short squeezes noted by Citi, but risks include regulatory changes and energy cost volatility. Investors should monitor ECB policy shifts and German economic indicators for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
